Skip to main content
JAMA Network logoLink to JAMA Network
. 2019 Jun 12;155(7):1. doi: 10.1001/jamadermatol.2019.1723

Errors in Figure 1 and Table 3

PMCID: PMC6563541  PMID: 31188396

In the Original Investigation titled “Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis,”1 published online first on May 10, 2019, there were errors in Figure 1 and in Table 3. In Figure 1, the width of the graphed line for the “infliximab optum” row should go to 8.02. In Table 3, all instances of “NA” should be deleted in the Reference Group (MTX), No., Pooled Patients column and in the Exposure Group, No., Pooled Patients column and replaced with the corresponding numbers of pooled patients. This article was corrected online.

Reference

  • 1.Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis [published online May 10, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.1121 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Dermatology are provided here courtesy of American Medical Association

RESOURCES